Abstract
Vancomycin is a primary regimen for treating MRSA and other Gram-positive \(\upbeta\)-lactam–resistant organisms. But the problem is the resistance to vancomycin, the clinical and microbiological characteristics in which it is used is always changing. Therefore, we conducted this retrospective study to analysis benefits of Vancomycin TDM in clinical outcomes and discovered the factors affecting on the vancomycin maintenance dose. We conducted a follow-up on 137 patients using vancomycin divided into two groups, including the TDM and non-TDM users. The evaluation criteria included panoramic vancomycin use, infection status, renal function and treatment results after ten days. The total number of samples taken from 79 patients applied TDM were 116 and 73.3% of the samples reached the target trough concentration. Compared to 58 patients of the non-TDM group, applying TDM will reduce c-reactive protein (CRP) and improve treatment outcome. We also found that the vancomycin trough concentration, creatinine clearance, and weight contributed significantly (24.7%, 16.8% and 26.6%, respectively) to the inter-individual variability in vancomycin dose. The multiple linear regression model for vancomycin maintenance dose was built as the formula: Vancomycin maintenance dose (mg/kg) = 21.4 + 0.24 * vancomycin trough concentration (µg/mL) + 0.17 * Clcr(mL/min) − 0.26 * weight(kg) + 0.17 * age(years) − 0.03 * ΔCRP. Our study demonstrated the benefits of vancomycin TDM technology on clinical outcomes and improvement of infection situation. Furthermore, we have successfully indicated a strong relationship between vancomycin trough concentration, creatinine clearance, age, weight, ΔCRP and maintenance dose of vancomycin. Clinicians in the process of designing a regimen dose of vancomycin should comprehensively consider these factors in order to optimize the dose and reduce the adverse effect of vancomycin.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Harkins CP et al (2017) Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol 18(1):130–130
Rybak M et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66(1):82–98
Brown J, Brown K, Forrest A (2012) Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 56(2):634–638
Harigaya Y et al (2009) Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother 53(9):3894–3901
Holmes NE et al (2013) Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 57(4):1654–1663
Kullar R et al (2011) Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52(8):975–981
LaPlante KL et al (2008) Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 52(6):2156–2162
Rybak MJ (2006) Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control 34(5):S38–S45
Ye ZK, Li C, Zhai SD (2014) Guidelines for therapeutic drug monitoring of vancomycin: a systematic review. PLoS One 9(6):e99044
Bellomo R et al (2004) Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 8(4):R204
Liang X et al (2018) A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. Clin Infect Dis 67(suppl_2):S249–S255
Lin Z et al (2014) Clinical research for trough value of serum vancomycin in critical patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 26(7):473–477
Acknowledgements
We thank all physicians and nurses of Haiphong International Hospital for their contributions to this study.
Conflicts of Interest
The authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this paper
Cite this paper
Phuong, N.T.T., Long, T.H., Anh, T.V., Hoi, N.T. (2022). Application of Vancomycin Therapeutic Drug Monitoring in a Vietnamese Private Hospital. In: Van Toi, V., Nguyen, TH., Long, V.B., Huong, H.T.T. (eds) 8th International Conference on the Development of Biomedical Engineering in Vietnam. BME 2020. IFMBE Proceedings, vol 85. Springer, Cham. https://doi.org/10.1007/978-3-030-75506-5_30
Download citation
DOI: https://doi.org/10.1007/978-3-030-75506-5_30
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-75505-8
Online ISBN: 978-3-030-75506-5
eBook Packages: EngineeringEngineering (R0)